Jeffrey R Rohde

US Patent:

8198331, Jun 12, 2012

Filed:

Feb 20, 2009

Appl. No.:

12/390286

Inventors:

R. Scott Bitner - Pleasant Prairie WI, US
Kaitlin E. Browman - Deerfield IL, US
Michael E. Brune - Mundelein IL, US
Steven Fung - Mount Prospect IL, US
Peer B. Jacobson - Libertyville IL, US
Lynne E. Rueter - Round Lake Beach IL, US
Marina I. Strakhova - Vernon Hills IL, US
Jiahong Wang - Lake Bluff IL, US
Jeffrey J. Rohde - Evanston IL, US
Qi Shuai - Dekalb IL, US
James T. Link - Stanford CA, US
Jyoti R. Patel - Libertyville IL, US
Jurgen Dinges - Wadsworth IL, US
Bryan K. Sorensen - Antioch IL, US
Hong Yong - Libertyville IL, US
Vince S. Yeh - San Diego CA, US
Ravi Kurukulasuriya - East Lyme CT, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 31/16

US Classification:

514613

Abstract:

The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

US Patent:

8415354, Apr 9, 2013

Filed:

Feb 20, 2009

Appl. No.:

12/390329

Inventors:

R. Scott Bitner - Pleasant Prairie WI, US
Kaitlin E. Browman - Deerfield IL, US
Michael E. Brune - Mundelein IL, US
Steven Fung - Mount Prospect IL, US
Peer B. Jacobson - Libertyville IL, US
Lynne E. Rueter - Round Lake Beach IL, US
Marina I. Strakhova - Vernon Hills IL, US
Jiahong Wang - Lake Bluff IL, US
James T. Link - Standford CA, US
Yixian Chen - Glenview IL, US
Hwan-soo Jae - Glencoe IL, US
Jyoti R. Patel - Libertyville IL, US
Marina A. Pliushchev - Vernon Hills IL, US
Jeffrey J. Rohde - Evanston IL, US
Qi Shuai - Dekalb IL, US
Bryan K. Sorensen - Antioch IL, US
Martin Winn - Deerfield IL, US
Dariusz Wodka - Monmouth Junction NJ, US
Hong Yong - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 31/65
A61K 31/445
A61K 31/496
C07C 233/05
C07D 211/00
C07D 401/04

US Classification:

51425212, 51425312, 514317, 544260, 544380, 546233, 564191, 585352

Abstract:

The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

US Patent:

20040048866, Mar 11, 2004

Filed:

Feb 26, 2003

Appl. No.:

10/375842

Inventors:

Teodozyj Kolasa - Lake Villa IL, US
Jorge Brioni - Vernon Hills IL, US
Vijaya Gracias - Lindenhurst IL, US
Masaki Nakane - Lake Bluff IL, US
Meena Patel - Green Oaks IL, US
Jeffrey Rohde - Evanston IL, US

International Classification:

A61K031/519
A61K031/502
A61K031/4745
A61K031/4162
C07D471/02
C07D487/02

US Classification:

514/248000, 514/262100, 514/303000, 544/236000, 544/262000, 546/118000, 514/406000, 548/361100

Abstract:

Compounds of formula (I) are novel indazoles useful for increasing cGMP levels in a mammal.

US Patent:

20050245532, Nov 3, 2005

Filed:

Apr 29, 2004

Appl. No.:

10/835132

Inventors:

Ethan Hoff - Racine WI, US
James Link - Evanston IL, US
Marina Pliushchev - Vernon Hills IL, US
Jeffrey Rohde - Evanston IL, US
Martin Winn - Deerfield IL, US

International Classification:

A61K031/495
A61K031/496
A61K031/445

US Classification:

514252120, 514254100, 514319000

Abstract:

The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.

US Patent:

20050245533, Nov 3, 2005

Filed:

Oct 14, 2004

Appl. No.:

10/965239

Inventors:

Ethan Hoff - Racine WI, US
James Link - Evanston IL, US
Marina Pliushchev - Vernon Hills IL, US
Jeffrey Rohde - Evanston IL, US
Martin Winn - Deerfield IL, US

International Classification:

A61K031/495
A61K031/496
A61K031/445

US Classification:

514252120, 514254100, 514319000

Abstract:

The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.

US Patent:

20050261302, Nov 24, 2005

Filed:

Apr 28, 2005

Appl. No.:

11/116849

Inventors:

Ethan Hoff - Racine WI, US
James Link - Evanston IL, US
Marina Pliushchev - Vernon Hills IL, US
Jeffrey Rohde - Evanston IL, US
Martin Winn - Deerfield IL, US

International Classification:

A61K031/495
A61K031/445
A61K031/40
A61K031/16

US Classification:

514252120, 514319000, 514408000, 514613000

Abstract:

The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.

US Patent:

20090054426, Feb 26, 2009

Filed:

Aug 21, 2008

Appl. No.:

12/195937

Inventors:

R. Scott Bitner - Pleasant Prairie WI, US
Kaitlin E. Browman - Deerfield IL, US
Michael E. Brune - Mundelein IL, US
Yixian Chen - Glenview IL, US
Jurgen Dinges - Wadsworth IL, US
Karla Drescher - Dossenheim, DE
Peer Jacobson - Libertyville IL, US
Hwan-soo Jae - Glencoe IL, US
Ravi Kurukulasuriya - Groton CT, US
James T. Link - Stanford CA, US
David J. Madar - Miami FL, US
Jyoti R. Patel - Libertyville IL, US
Marina A. Pliushchev - Vernon Hills IL, US
Jeffrey J. Rohde - Evanston IL, US
Lynne E. Rueter - Round Lake Beach IL, US
Qi Shuai - Dekalb IL, US
Bryan K. Sorensen - Antioch IL, US
Jiahong Wang - Lake Bluff IL, US
Karsten M. Wicke - Altrip, DE
Martin Winn - Deerfield IL, US
Dariusz Wodka - Monmouth Junction NJ, US
Vince Yeh - LaJolla CA, US
Hong Yong - Libertyville IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

A61K 31/496
A61P 25/00
A61K 31/5375
A61K 31/445
A61K 31/16

US Classification:

5142312, 51425301, 514325, 514408, 514623

Abstract:

A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.

US Patent:

20130045978, Feb 21, 2013

Filed:

Jun 22, 2012

Appl. No.:

13/530422

Inventors:

R. Scott Bitner - Pleasant Prairie WI, US
Kaitlin E. Browman - Deerfield IL, US
Michael E. Brune - Mundelein IL, US
Steven Fung - Mount Prospect IL, US
Peer B. Jacobson - Libertyville IL, US
Lynne E. Rueter - Round Lake Beach IL, US
Marina I. Strakhova - Vernon Hills IL, US
Jiahong Wang - Lake Bluff IL, US
Jyoti R. Patel - Libertyville IL, US
Qi Shuai - Dekalb IL, US
James T. Link - Stanford CA, US
Jeffrey J. Rohde - Evanston IL, US
Jurgen Dinges - Wadsworth IL, US
Bryan K. Sorensen - Antioch IL, US
Martin Winn - Deerfield IL, US
Hong Yong - Libertyville IL, US
Vince S. Yeh - San Diego CA, US

International Classification:

A61K 31/16
A61K 31/196
A61K 31/27
A61K 31/44
A61K 31/277
A61K 31/41
A61K 31/4439
A61K 31/5375
A61P 3/10
A61P 3/04
A61P 3/00
A61P 9/12
A61P 25/28
A61P 25/24
A61P 25/22
A61P 25/18
A61K 31/165

US Classification:

5142392, 514616, 514563, 514622, 514480, 514346, 514511, 514381, 514341

Abstract:

The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.